Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure

Nicholas G Theodorakis, Yining N Wang, Vyacheslav A Korshunov, Mary A Maluccio, Nicholas J Skill

AIM: Portal hypertension is a common complication of liver cirrhosis and significantly increases mortality and morbidity. Previous reports have suggested that the compound thalidomide attenuates portal hypertension (PHT). However, the mechanism for this action is not fully elucidated. One hypothesis is that thalidomide destabilizes tumor necrosis factor α (TNFα) mRNA and therefore diminishes TNFα induction of nitric oxide synthase (NOS) and the production of nitric oxide (NO). To examine this hypothesis, we utilized the murine partial portal vein ligation (PVL) PHT model in combination with endothelial or inducible NOS isoform gene knockout mice.

METHODS: Wild type, inducible nitric oxide synthase (iNOS)−/− and endothelial nitric oxide synthase (eNOS)−/− mice received either PVL or sham surgery and were given either thalidomide or vehicle. Serum nitrate (total nitrate, NOx) was measured daily for 7 d as a surrogate of NO synthesis. Serum TNFα level was quantified by enzyme-linked immunosorbent assay. TNFα mRNA was quantified in liver and aorta tissue by reverse transcription-polymerase chain reaction. PHT was determined by recording splenic pulp pressure (SPP) and abdominal aortic flow after 0-7 d. Response to thalidomide was determined by measurement of SPP and mean arterial pressure (MAP).

RESULTS: SPP, abdominal aortic flow (Qao) and plasma NOx were increased in wild type and iNOS−/− PVL mice when compared to sham operated control mice. In contrast, SPP, Qao and plasma NOx were not increased in eNOS−/− PVL mice when compared to sham controls. Serum TNFα level in both sham and PVL mice was below the detection limit of the commercial ELISA used. Therefore, the effect of thalidomide on serum TNFα levels was undetermined in wild type, eNOS−/− or iNOS−/− mice. Thalidomide acutely increased plasma NOx in wild type and eNOS−/− mice but not iNOS−/− mice. Moreover, thalidomide temporarily (0-90 min) decreased mean arterial pressure, SPP and Qao in wild type, eNOS−/− and iNOS−/− PVL mice, after which time levels returned to the respective baseline.

CONCLUSION: Thalidomide does not reduce portal
pressure in the murine PVL model by modulation of NO biosynthesis. Rather, thalidomide reduces PHT by decreasing MAP by an undetermined mechanism.

Key words: Portal hypertension; Thalidomide; Nitric oxide; Knockout mice; Endothelial nitric oxide synthase; Inducible nitric oxide synthase; Tumor necrosis factor alpha

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The research innovation detailed in this manuscript is the use of nitric oxide synthase (NOS) isoform specific gene deleted mice to better understand the underlying mechanisms for the development of portal hypertension (PHT). PHT is a significant complication of liver disease and increases morbidity and mortality. Our study examined the hypothesis that the compound thalidomide reduces PHT by decreasing the biosynthesis of nitric oxide (NO) via destabilizing tumor necrosis factor alpha mRNA levels. We demonstrate that thalidomide induces NO via increased inducible nitric oxide synthase isoform of NOS; however, thalidomide reduction in PHT was NOS isoform independent.


INTRODUCTION

Portal hypertension (PHT) is a complication typically associated with underlying liver disease whereby portal pressure exceeds 10 mmHg[1]. In general, PHT is predominantly a sequela of alcoholic, non-alcoholic steatohepatitis or viral cirrhosis[2] and is augmented by the formation of a systemic hyper-dynamic circulation manifesting as a generalized reduced vascular resistance, via vasodilatation, promoting systemic and mesenteric hyperemia[3,4]. Increased hepatic resistance in combination with hyperemia promotes redirection of portal venous flow from the liver towards, via sinusoid constriction and increased hepatic resistance to portal venous flow[5]. In contrast, increased extra-hepatic vascular eNOS promotes vasodilation and the development of hyper-dynamic circulation by increasing blood flow to the liver[6,7,8]. Moreover, functional eNOS is also found in circulating micro-particles (< 1 μm) shed from endothelial and blood cells. Studies show that micro-particles are increased in patients with endothelial dysfunction but eNOS expression is decreased[9]. Consequently, the precise mechanism/role for eNOS in PHT is not clear. We do know that eNOS activation is multifaceted and includes protein kinase B AKT, GTPase-activating protein, sarcoma proto-oncogene and G protein-coupled receptor-2 kinase activity culminating with eNOS phosphorylation and translocation to the cell membrane[6,14-16].

In addition, the cytokine tumor necrosis factor alpha (TNF-α) is thought to be important in the pathogenesis of PHT by increasing eNOS activity and NO production[17,18]. Therefore, inhibition of TNFα has the potential to ameliorate portal pressure and reduce mortality and morbidity associated with PHT. Previous studies have shown that the compound thalidomide destabilizes TNFα mRNA[19] and prevents the development of PHT in portal vein ligated (PVL) animals[20,21]. However, the precise mechanism by which thalidomide abrogates PHT is not fully understood. In human studies, thalidomide reduces hepatic venous pressure gradient without reducing systemic hemodynamic parameters[22]. This suggests that: (1) TNFα is not associated with PHT associated hyper-dynamic circulation; and (2) thalidomide reduces PHT independent of TNFα and NO.

To examine the mechanistic connection between thalidomide, TNFα and NO on PHT, we utilized the murine, non-inflammatory, pre-hepatic PVL model of PHT and commercially available iNOS and eNOS gene knockout mice and examined changes to TNFα and PHT in response to thalidomide. We have previously shown that in the PVL model of PHT, eNOS is the dominant NOS isoform and in its absence PHT does not develop[9]. We anticipated that in PVL mice, TNFα would be increased and that thalidomide would reduce this increase and associated PHT but there would be no response to thalidomide in eNOS-/- mice. In contrast to this expectation, we found that TNFα levels were below detectable limits of the enzyme-linked immunosorbent assay (ELISA) used and that thalidomide caused: (1) an iNOS dependent increase in circulating NOx levels; and (2) thalidomide reduction of portal pressure was NOS isoform independent and was commensurate with a NOS independent drop in systolic blood pressure. Because TNFα levels in mice were below detectable levels, we were unable to determine response to thalidomide administration. Liver and thoracic aorta tissue TNFα mRNA expression levels were detectable and levels were not significantly decreased hepatic eNOS results in hepatic sinusoid constriction and increased hepatic resistance to portal venous flow[10]. In contrast, increased extra-hepatic vascular eNOS promotes vasodilation and the development of hyper-dynamic circulation by increasing blood flow to the liver[11,12]. Moreover, functional eNOS is also found in circulating micro-particles (< 1 μm) shed from endothelial and blood cells. Studies show that micro-particles are increased in patients with endothelial dysfunction but eNOS expression is decreased[13]. Consequently, the precise mechanism/role for eNOS in portal venous flow from the liver towards, in combination with liver failure significantly have the greatest capacity for hemorrhage amongst varices and in combination with hepatic resistance significantly increase mortality and morbidity[19].

Previous studies have detailed the importance of nitric oxide synthase (NOS) enzymes in the development of PHT. In particular, the NOS isoform endothelial NOS (eNOS) is thought to be important to PHT by regulating biosynthesis of the potent vasodilator nitric oxide (NO)[7-9]. Decreased hepatic eNOS results in hepatic sinusoid constriction and increased hepatic resistance to portal venous flow[10]. In contrast, increased extra-hepatic vascular eNOS promotes vasodilation and the development of hyper-dynamic circulation by increasing blood flow to the liver[11,12]. Moreover, functional eNOS is also found in circulating micro-particles (< 1 μm) shed from endothelial and blood cells. Studies show that micro-particles are increased in patients with endothelial dysfunction but eNOS expression is decreased[13]. Consequently, the precise mechanism/role for eNOS in PHT is not clear. We do know that eNOS activation is multifaceted and includes protein kinase B AKT, GTPase-activating protein, sarcoma proto-oncogene and G protein-coupled receptor-2 kinase activity culminating with eNOS phosphorylation and translocation to the cell membrane[6,14-16].

In addition, the cytokine tumor necrosis factor alpha (TNF-α) is thought to be important in the pathogenesis of PHT by increasing eNOS activity and NO production[17,18]. Therefore, inhibition of TNFα has the potential to ameliorate portal pressure and reduce mortality and morbidity associated with PHT. Previous studies have shown that the compound thalidomide destabilizes TNFα mRNA[19] and prevents the development of PHT in portal vein ligated (PVL) animals[20,21]. However, the precise mechanism by which thalidomide abrogates PHT is not fully understood. In human studies, thalidomide reduces hepatic venous pressure gradient without reducing systemic hemodynamic parameters[22]. This suggests that: (1) TNFα is not associated with PHT associated hyper-dynamic circulation; and (2) thalidomide reduces PHT independent of TNFα and NO.

To examine the mechanistic connection between thalidomide, TNFα and NO on PHT, we utilized the murine, non-inflammatory, pre-hepatic PVL model of PHT and commercially available iNOS and eNOS gene knockout mice and examined changes to TNFα and PHT in response to thalidomide. We have previously shown that in the PVL model of PHT, eNOS is the dominant NOS isoform and in its absence PHT does not develop[9]. We anticipated that in PVL mice, TNFα would be increased and that thalidomide would reduce this increase and associated PHT but there would be no response to thalidomide in eNOS-/- mice. In contrast to this expectation, we found that TNFα levels were below detectable limits of the enzyme-linked immunosorbent assay (ELISA) used and that thalidomide caused: (1) an iNOS dependent increase in circulating NOx levels; and (2) thalidomide reduction of portal pressure was NOS isoform independent and was commensurate with a NOS independent drop in systolic blood pressure. Because TNFα levels in mice were below detectable levels, we were unable to determine response to thalidomide administration. Liver and thoracic aorta tissue TNFα mRNA expression levels were detectable and levels were not significantly decreased hepatic eNOS results in hepatic sinusoid constriction and increased hepatic resistance to portal venous flow[10]. In contrast, increased extra-hepatic vascular eNOS promotes vasodilation and the development of hyper-dynamic circulation by increasing blood flow to the liver[11,12]. Moreover, functional eNOS is also found in circulating micro-particles (< 1 μm) shed from endothelial and blood cells. Studies show that micro-particles are increased in patients with endothelial dysfunction but eNOS expression is decreased[13]. Consequently, the precise mechanism/role for eNOS in PHT is not clear. We do know that eNOS activation is multifaceted and includes protein kinase B AKT, GTPase-activating protein, sarcoma proto-oncogene and G protein-coupled receptor-2 kinase activity culminating with eNOS phosphorylation and translocation to the cell membrane[6,14-16].

In addition, the cytokine tumor necrosis factor alpha (TNF-α) is thought to be important in the pathogenesis of PHT by increasing eNOS activity and NO production[17,18]. Therefore, inhibition of TNFα has the potential to ameliorate portal pressure and reduce mortality and morbidity associated with PHT. Previous studies have shown that the compound thalidomide destabilizes TNFα mRNA[19] and prevents the development of PHT in portal vein ligated (PVL) animals[20,21]. However, the precise mechanism by which thalidomide abrogates PHT is not fully understood. In human studies, thalidomide reduces hepatic venous pressure gradient without reducing systemic hemodynamic parameters[22]. This suggests that: (1) TNFα is not associated with PHT associated hyper-dynamic circulation; and (2) thalidomide reduces PHT independent of TNFα and NO.

To examine the mechanistic connection between thalidomide, TNFα and NO on PHT, we utilized the murine, non-inflammatory, pre-hepatic PVL model of PHT and commercially available iNOS and eNOS gene knockout mice and examined changes to TNFα and PHT in response to thalidomide. We have previously shown that in the PVL model of PHT, eNOS is the dominant NOS isoform and in its absence PHT does not develop[9]. We anticipated that in PVL mice, TNFα would be increased and that thalidomide would reduce this increase and associated PHT but there would be no response to thalidomide in eNOS-/- mice. In contrast to this expectation, we found that TNFα levels were below detectable limits of the enzyme-linked immunosorbent assay (ELISA) used and that thalidomide caused: (1) an iNOS dependent increase in circulating NOx levels; and (2) thalidomide reduction of portal pressure was NOS isoform independent and was commensurate with a NOS independent drop in systolic blood pressure. Because TNFα levels in mice were below detectable levels, we were unable to determine response to thalidomide administration. Liver and thoracic aorta tissue TNFα mRNA expression levels were detectable and levels were not significantly
changed in response to PVL surgery but were increased following thalidomide administration. This information demonstrates that thalidomide improves portal hemodynamics independent of NO and is linked to a reduction in mean arterial blood pressure.

MATERIALS AND METHODS

Unless otherwise stated, all chemicals were purchased from Sigma, MO. The partial portal vein ligation pre-hepatic PHT model was used. All studies were approved by the University of Rochester committee for animal research and adhered to AAALC and federal guidelines for the humane care and treatment of animals. Mice were maintained in sterilized isoflour cages on a 12-h light/dark cycle and were allowed access to food and water ad libitum. Mice [C57B/6J, C57BL/6J-NOS2tm1Unc (iNOS−/−)]23 and C57BL/6J-NOS3tm1Unc (eNOS−/−)24 (Jackson Labs, MA) were anesthetized using halothane inhalation. A midline laparotomy was performed and the portal vein was exposed. A blunt-ended 27-gauge needle was placed alongside the portal vein and a 4-0 silk suture was tied around the vein and needle, after which the needle was withdrawn, producing a standardized stenosis. In sham animals, the procedure consisted of dissection and visual inspection of the portal vein without ligation. The abdomen was closed and the animals were allowed to recover under a heat lamp. For thalidomide administration: plasma TNFα and NOx levels following PVL or thalidomide were determined following sham or PVL ligation and after thalidomide injection. TNFα levels were below the detectable levels of the assay. Consequently, no increase was detected following PVL and no decrease following thalidomide injection. TNFα levels were estimated using ANOVA statistical analysis (SPSS, IBM).

Physiological measurements

Physiological measurements were performed as previously described[9]. At the indicated times post sham-operation or PVL animals were anesthetized (halothane) and subjected to laparotomy to allow physiological measurements to be taken. Splenic pulp pressure (SPP) was measured as an index of portal venous pressure. To measure SPP, a cannula made from a 25-gauge needle connected to a saline-filled manometer was inserted into the spleen pulp. Abdominal aortic flow was measured by placing an ultrasonic Doppler flow probe (Transonic #11RB) around the abdominal aorta between the diaphragm and celiac artery. Flow rates were obtained with a Transonic T206 Blood Flow Meter (Transonic Instruments, Ithaca, NY). Aortic blood flows were standardized per gram of body weight.

Systolic blood pressure and heart rate were determined by non-invasive tail cuff plethysmography using the Visitech BP-2000 Blood Pressure Analysis system as per manufacturer’s instructions (Visitech systems, Apex, NC). Baseline values were obtained for 4 d to train the mice (n = 8) in the measurement of blood pressure and heart rate. On the fifth day, mice were given 50 mg/kg thalidomide and the blood pressure and heart rate was calculated for 10 min every 20 min.

Plasma TNFα and NOx levels

Blood was collected by cardiac puncture, injected into heparinized tubes and centrifuged. Plasma TNFα was measured by sandwich ELISA in accordance with manufacturer’s instructions (#MTA00B, RD systems, Minneapolis, MN). TNFα was measured 0, 1, 3, 6, 12, 16, 20 and 24 h and 2, 3, 4, 5, 6 and 7 d following PVL operation. Plasma NOx was determined using the Griess reaction25 using a commercially available kit (#NB98, Oxford Biomedical, Rochester Hills, MI).

In vitro cell culture: RAW264 mouse macrophage cells (#TIB-71 ATCC, Manassas, VI) were cultured in the presence or absence of LPA and/or 25-100 μg/mL thalidomide for 0–24 h.

Gene expression: TNFα, eNOS and iNOS mRNA from liver, aorta or RAW264 cells were determined by reverse transcription-polymerase chain reaction (RT-PCR) using gene-specific primers (200 ng) and 1 μg cDNA: eNOS: 5’GTGTAAGGGCCACCTCTG 3’ACTCATCCATG CACAGGACC, INOS: 5’GCCCTACGGGTAGACAGCA 3’TGCCTATTCG TGGGACAGTC TNFα 5’CTGGACGCA CAGTGCGTGAC 3’TTGAGATCCCGGAGCGG 3’TGCCCATTTG CTTCCAGCGT CTCGAGCTCGCGGATG (cycle = 1 min each of 94° c, 90° c and 4°C x 35). Primers were purchased from Life Technologies, Grand Island, NY.

Statistical analysis

The data shown are mean ± SE, with 3–7 animals per experimental group. Statistical significance was estimated using ANOVA statistical analysis (SPSS, IBM).

RESULTS

TNF-α and NOx levels following PVL or thalidomide administration: plasma TNFα and NOx levels were determined following sham or PVL ligation and after thalidomide injection. TNFα levels were below the detectable levels of the assay. Consequently, no increase was detected following PVL and no decrease following thalidomide injection. Injection of 1 mg/kg LPS increased serum TNFα and NOx levels following PVL surgery (Figure 1A). This PVL induced NOx at 100 mg/kg. No change in eNOS expression was
in immortalized macrophage cells (RAW263.3), we found that thalidomide reduced TNFα mRNA in unstimulated and LPS stimulated cells (81.7% and 78.6% respectively). In contrast, thalidomide did not reduce LPS stimulated iNOS mRNA induction.

Effects of thalidomide on mean blood pressure, heart rate and portal hemodynamics following PVL: in vehicle treated mice, splenic pulp pressure and abdominal aortic flow were increased significantly 7 d following PVL (Table 1). Treatment of mice with 50 mg/kg thalidomide resulted in a temporary (90 min) reduction in elevated splenic pressure and mean systolic blood pressure (58% and 70% reduction respectively) (Figure 2A and B). Thalidomide induced reduction was maximal 30–60 min following injection and after which time splenic pulp pressure and mean arterial pressure recovered to an elevated level by 90 min. No significant change in heart rate was observed following thalidomide administration in PVL or sham mouse groups.

Role of NOS isoforms on thalidomide: to determine the effect of thalidomide in vivo was determined by quantification of hepatic and arterial tissue TNFα, eNOS and iNOS expression ± thalidomide by RT-PCR. TNFα mRNA was increased by 62% in thoracic aorta tissues and 34% in the liver tissues. In a similar manner, hepatic iNOS was increased 70% and 49% respectively. No change in eNOS mRNA was observed.

The effect of thalidomide in vivo was determined by quantification of hepatic and arterial tissue TNFα, eNOS and iNOS expression ± thalidomide by RT-PCR. TNFα mRNA was increased by 62% in thoracic aorta tissues and 34% in the liver tissues. In a similar manner, hepatic iNOS was increased 70% and 49% respectively. No change in eNOS mRNA was observed.

Hepatic and arterial TNFα, eNOS and iNOS expression following thalidomide administration: thalidomide is reported to destabilize TNFα mRNA[19]. In immortalized macrophage cells (RAW263.3), we found that thalidomide reduced TNFα mRNA in unstimulated and LPS stimulated cells (81.7% and 78.6% respectively). In contrast, thalidomide did not reduce LPS stimulated iNOS mRNA induction.

### Table 1  Splenic pulp pressure and abdominal aortic flow 7 d post portal vein ligation or sham

<table>
<thead>
<tr>
<th>Group</th>
<th>Splenic pulp pressure (cmH2O)</th>
<th>Abdominal aortic flow (mL/min per gram)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type sham</td>
<td>6.9 ± 0.4</td>
<td>0.17 ± 0.02</td>
</tr>
<tr>
<td>Wild type 7 d PVL</td>
<td>25.4 ± 3.1*</td>
<td>0.27 ± 0.04*</td>
</tr>
<tr>
<td>eNOS−/− sham</td>
<td>6.9 ± 0.3</td>
<td>0.15 ± 0.01</td>
</tr>
<tr>
<td>eNOS−/− 7 d PVL</td>
<td>7 ± 0.5</td>
<td>0.15 ± 0.01</td>
</tr>
<tr>
<td>iNOS−/− 7 d sham</td>
<td>6.7 ± 1</td>
<td>0.16 ± 0.01</td>
</tr>
<tr>
<td>iNOS−/− 7 d PVL</td>
<td>21.1 ± 0.4*</td>
<td>0.23 ± 0.06*</td>
</tr>
</tbody>
</table>

*P < 0.05 vs wild type sham; †P < 0.05 vs iNOS−/− 7 d sham; mean ± SE (n = 4–7). iNOS: Inducible nitric oxide synthase.

---

![Figure 1](image1.png)

**Figure 1** Portal vein ligation and thalidomide increases nitric oxide via endothelial and inducible nitric oxide synthase respectively. Plasma total nitrate (NOx) was measured daily for 7 d in wild type (WT), endothelial nitric oxide synthase (eNOS)−/− and inducible nitric oxide synthase (iNOS)−/− mice following portal vein ligation (PVL) or sham surgery. A: Plasma NOx increased following PVL in wild type mice but not following sham surgery. Levels increased to a maximum 2 d after PVL after which NOx returned to pre-surgical baseline; B: Plasma NOx increased 2 d following PVL in iNOS−/− but not eNOS mice. In eNOS−/− mice NO was not increased following PVL; C: Unadulterated 8 wk WT, eNOS−/− and iNOS−/− mice were given 50 mg/kg thalidomide or vehicle. Blood was collected by cardiac puncture and plasma was assayed for NOx. Plasma NOx was significantly increased by the administration of thalidomide in WT and eNOS−/− mice but was reduced in iNOS−/− mice. *P < 0.05 vs other groups.
The role of NOS isoforms on the transient hemodynamic response to thalidomide, wild type, eNOS\textsuperscript{-/-} and iNOS\textsuperscript{-/-} 7 d PVL mice were treated with 50 mg/kg thalidomide ip and splenic pulp pressure was measured 0-150 min following administration. Splenic pulp pressure was rapidly and temporarily decreased by thalidomide; after 2 h pressure returned back to pre-thalidomide levels; B: Systolic blood pressure was also measured in 7 d PVL wild type mice following the administration of 50 mg/kg thalidomide or vehicle control. In a similar manner to splenic pulp pressure the systolic blood pressure was temporarily decreased by thalidomide. \( P < 0.05 \) vs control group.

Theodorakis NG et al. PHT and NOS isoforms

**DISCUSSION**

In 1998, the US Food and Drug Administration approved the use of thalidomide for the treatment of leprosy and multiple myeloma. Additional research has investigated the benefit of thalidomide in animal models of Alzheimer’s\textsuperscript{[26]}, pancreatitis\textsuperscript{[27]}, colitis\textsuperscript{[28]} and PHT\textsuperscript{[20]}. The purpose of this manuscript is not to advocate the use of thalidomide for the treatment of PHT. That claim is beyond the scope of our experimental studies and we leave that analysis for others. Using the PVL murine model of pre-hepatic PHT in eNOS\textsuperscript{-/-} and INOS\textsuperscript{-/-} deficient animals, this study investigates thalidomide abrogation of PHT via mediating activation of NO.
production. Our data shows that thalidomide increases NO production, via induction of iNOS, but this increase is not important to thalidomide transient reduction of PHT. Moreover, given that TNF-α expression in liver and aorta tissues was unchanged in response to PVL, the murine PVL model is not suitable to study the role of TNF-α in PHT. However, the demonstration that thalidomide temporarily reduces mean systemic blood pressure by an NO independent mechanism illustrates that thalidomide may be beneficial to prevent variceal formation and hemorrhage, a common problem associated with PHT, especially in patients that are non-responsive to current β-blocker therapy to reduce systemic blood pressure[29].

The scientific consensus is that the vasodilator NO plays a major role in the development and sustained vasculopathy of PHT[4]. However, the mechanisms controlling NO biosynthesis in the context of PHT are not clearly defined. Previous investigations using animal models of PHT and human studies suggest a role for TNF-α in vasodilatation by promoting increased NO production[30] by arguing that TNF-α induction of NOS isoforms (eNOS, and/or iNOS) promotes the development of a hyper-dynamic circulation and vascular hypo-responsiveness to vasoconstrictors associated with this pathological dysfunction[31]. Therefore, inhibition of TNF-α is a potential mechanism in which to reduce PHT. Previous studies have shown that the compound thalidomide reduces TNF-α[8,32]. The purpose of this manuscript was to investigate the hypothesis that TNF-α modulates PHT via nitric oxide synthase enzyme[33]. We found that thalidomide, rather than reduce NO levels, increased circulating plasma NOx levels via iNOS. Moreover, although

**Figure 4** Portal vein ligation does not increase hepatic or aortic tumor necrosis factor alpha mRNA expression. Pre-hepatic portal hypertension was induced in wild type mice by partial ligation of the portal vein. 0-24 h post ligation livers (A) and thoracic aortas (B) were harvested and quantified for tumor necrosis factor (TNF) mRNA by reverse transcription-polymerase chain reaction. TNF-α was not changed within livers and aorta following portal vein ligation (PVL). Figures are representative of three experiments. Hepatic (C) and aortic (D) TNF-α expression was unchanged 0-4 d post PVL. Line graphs represent mean ± SE. n = 5 mice.
Thalidomide does reduce TNFα mRNA levels in mouse macrophage cells (RAW264.3), thalidomide increased TNFα and iNOS mRNA expression in murine liver and thoracic aorta tissues, suggesting that in vivo thalidomide increases TNFα and iNOS levels. It is not unexpected that thalidomide would modulate TNFα and iNOS similarly as co-regulation of TNFα and iNOS in response to stimuli is well described[34,35], as is the interaction between TNFα expression and iNOS expression[36,37]. Moreover, TNFα neutralizing antibodies are known to reduce iNOS expression[38-40].

Despite detecting an increase in TNFα expression, we were unable to detect circulating TNFα in sham or PVL mice irrespective of thalidomide administration using a highly specific commercially available ELISA, arguing against a role for TNFα in PVL models of PHT. However, studies by others have detected TNFα in rodent models of PVL using biological cell based assays[20]. The fact that TNFα neutralizing antibodies reduce NO and portal pressure in PVL rats suggests that TNFα is important in the PVL model via modulation of NOS[10]. Although TNFα levels were undetectable, the effects of thalidomide on NOS isoforms can be determined by measuring circulating NO levels, hemodynamic changes and TNFα mRNA levels.

In rat PHT models, thalidomide administration demonstrated a significant correlation between TNFα plasma levels and mean arterial pressure among PVL animals[40]. Thalidomide has been noted to have many possible vascular effects, including anti-angiogenesis[41], disruption of mRNA transcription causing attenuation of the nuclear factor kappa B mediated gene expression[42], increase of the production of free radicals to elicit oxidative stress[43] and directly through systemic circulatory and/or direct cardiac effects[44]. Consequently, a therapeutic role for thalidomide in patients with cirrhosis has been proposed[22]. We found that thalidomide reduced PHT via a significant reduction in mean arterial pressure (MAP) that was NOS isoform independent and irrelevant to circulating NO levels. MAP is approximately determined from measurements of the systolic pressure and the diastolic pressure over a cardiac cycle and is determined by the cardiac output (CO), systemic vascular resistance (SVR) and central venous pressure [MAP = (CO - SVR) + CVR]. Cardiac output is related to both heart rate and stroke volume (SV). Both thalidomide and TNFα have been linked to vascular regulation.

Thalidomide has been shown to improve CO by increasing the left ventricular ejection fraction[44,45] and causes an imbalance between vasodilators (NO) and vasoconstrictors (endothelin-1) that impacts SVR[46]. Our data suggests that modulation of NO is linked to iNOS. Studies by others have reported that thalidomide does not change endothelin-1 levels in human endothelial cells[47]. While the vascular response to thalidomide was not the original focus of this study, we did observe that heart rate was not affected by thalidomide. This suggests changes in SVR, CVR or SV. TNFα has been shown to directly increase cardiac index and mean arterial pressure, systemic vascular resistance index, temperature, and heart rate[48,49]. However, because there appears to be no discernable increase in TNFα within the PVL murine model of PHT, other models are required to fully understand the connections amongst TNFα, thalidomide and PHT.

In conclusion, although previous reports demonstrate the importance of TNFα in the development of PHT, TNFα does not appear to be important in the murine PVL model. This correlates with our previous study demonstrating that gene deletion of TNFα receptors does not ameliorate PHT in mice following PVL[50]. Consequently, the PVL model of PHT is not conducive to the study of TNFα in PHT. Despite this lack of TNFα involvement, thalidomide treatment demonstrated a temporary reduction in PHT via a NOS isoform independent mechanism, indicating a non-TNFα and non-NO mechanism for thalidomide in PHT. While this observation is interesting because thalidomide may be beneficial for the treatment of PHT associated variceal formation and bleeding, the use of thalidomide is cautioned since thalidomide is associated with thromboembolic events that would exacerbate PHT and enhance liver damage[51]. However, use of thalidomide analogs may demonstrate therapeutic benefit without vascular complications[52]. Further investigation is required to better understand the mechanism by which thalidomide reduces portal pressure with the anticipation that advances can be translated to clinical practice and improve outcomes for patients with liver disease and a high risk of developing PHT. We do not suggest by what mechanism thalidomide reduces mean arterial blood pressure because thalidomide is linked to many biological mechanisms, including vascular endothelial growth factor and thromboxane, both of which have been linked to PHT[53-55]. Moreover, thalidomide is known to modulate PHT via cannabinoid receptor-2 (CB2) expression and studies show that targeting CB2 receptor agonists ameliorate PHT in bile duct ligated rats and that thalidomide increases CB2 receptor expression and reduces cannabinoid receptor-1 expression[56,57].

ACKNOWLEDGMENTS

The authors would like to thank Dr. James Sitzmann and Dr. Brad Berk, University of Rochester School of Medicine, for fostering the completion of this work.

COMMENTS

Background

Portal hypertension is an elevation in the portal venous pressure and increases mortality and morbidity in patients. The compound thalidomide has been shown to reduce portal hypertension. However, the mechanism of this response is unclear and the use of thalidomide is controversial. Previous studies have demonstrated that thalidomide reduces biosynthesis of the potent vasodilator nitric oxide (NO) by destabilizing tumor necrosis factor alpha mRNA. The
purpose of this study was to test this hypothesis using mice that have targeted gene deletions affecting NO biosynthesis.

**Research frontiers**

There is a need to find alternative treatment paradigms for treating portal hypertension, including diagnosis, measurement and treatment. Thalidomide has been shown to reduce portal pressure and thalidomide derivatives are being explored. The hot spot is to better understand how these compounds work in order to facilitate translation in to the clinic.

**Innovations and breakthroughs**

The innovation of this research is the utilization of gene deleted mice and the microsurgery. In combination, this provides a cleaner understanding of the role of individual genes within disease pathology. The portal vein ligation model avoids the inflammatory and cytokine milieu associated with the carbon tetrachloride or bile duct ligation models of portal hypertension.

**Applications**

This study confirms that thalidomide does reduce portal hypertension but that this response is transient and last about 1 hour. Moreover, the reduction is not linked to NO biosynthesis but via a nitric oxide synthase (NOS) independent reduction in microvasculature. These results support the use of thalidomide or its derivatives and will direct further studies to investigate alternative targets other than NO.

**Terminology**

Portal hypertension is driven by two main pathologies and both are related to NO. Reduced hepatic NO biosynthesis causes sinusoidal constriction that increases resistance to portal flow and increases portal pressure. In contrast, NO is increased within the systemic vasculature, resulting in increased cardiac output and increased portal venous flow that increase portal pressure.

**Peer-review**

The authors examined the hypothesis that thalidomide diminishes tumor necrosis factor alpha induction of NOS and the production of NO. They concluded that the transitory reduction in portal pressure was associated with an inducible NOS dependent increase in NO and a NOS isoform independent reduction in blood pressure.

**REFERENCES**


22. Austin AS, Mahida YR, Clarke D, Ryder SD, Freeman JG. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. *Aliment Pharmacol Ther* 2004; 19: 79-88 [PMID: 14687169]


[PMID: 16133968 DOI: 10.1007/s10620-005-2941-0]


Huang HC, Wang SS, Hsun IF, Chang CC, Lee FY, Lin HC, Chung CL, Lee JY, Hsieh HG, Lee SD. Cannabinoid receptor 2...
